Jeffrey L Carson, MD
Study Chair
Principal Investigator, Clinical Coordinating Center
Rutgers Robert Wood Johnson Medical School

Maria Mori Brooks, PhD
Principal Investigator, Data Coordinating Center
University of Pittsburgh

Version 6.0
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>INTRODUCTION</td>
<td>8</td>
</tr>
<tr>
<td>A1</td>
<td>STATEMENT OF COMPLIANCE</td>
<td>8</td>
</tr>
<tr>
<td>A2</td>
<td>STUDY ABSTRACT</td>
<td>9</td>
</tr>
<tr>
<td>A3</td>
<td>PRIMARY HYPOTHESIS</td>
<td>9</td>
</tr>
<tr>
<td>A4</td>
<td>PURPOSE OF THE STUDY PROTOCOL</td>
<td>10</td>
</tr>
<tr>
<td>A5</td>
<td>SCHEMATIC OF STUDY DESIGN</td>
<td>11</td>
</tr>
<tr>
<td>A6</td>
<td>KEY ROLES</td>
<td>12</td>
</tr>
<tr>
<td>B</td>
<td>BACKGROUND</td>
<td>13</td>
</tr>
<tr>
<td>B1</td>
<td>PRIOR LITERATURE AND STUDIES</td>
<td>13</td>
</tr>
<tr>
<td>B2</td>
<td>RATIONALE FOR THIS STUDY: EQUIPOISE</td>
<td>17</td>
</tr>
<tr>
<td>C</td>
<td>STUDY OBJECTIVES</td>
<td>18</td>
</tr>
<tr>
<td>C1</td>
<td>PRIMARY AIM</td>
<td>18</td>
</tr>
<tr>
<td>C2</td>
<td>SECONDARY AIMS</td>
<td>18</td>
</tr>
<tr>
<td>C3</td>
<td>TERTIARY AIMS</td>
<td>18</td>
</tr>
<tr>
<td>C4</td>
<td>RATIONALE FOR THE SELECTION OF OUTCOME MEASURES</td>
<td>19</td>
</tr>
<tr>
<td>D</td>
<td>STUDY DESIGN</td>
<td>20</td>
</tr>
<tr>
<td>D1</td>
<td>OVERVIEW OR DESIGN SUMMARY</td>
<td>20</td>
</tr>
<tr>
<td>D2</td>
<td>SUBJECT SELECTION AND WITHDRAWAL</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Inclusion Criteria</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Exclusion Criteria</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Ethical Considerations</td>
<td>22</td>
</tr>
</tbody>
</table>
6.a Safety and Compliance Monitoring ................................................................. 30
6.b Medical Monitoring ....................................................................................... 30
   i Investigator Only ......................................................................................... 30
   ii Independent Expert to Monitor ................................................................. 31
   iii Independent Data and Safety Monitoring Board ..................................... 31
6.c Definitions of Adverse Events ................................................................. 32
6.d Classification of Events ........................................................................... 33
   i Severity ....................................................................................................... 33
   ii Relationship .............................................................................................. 33
   iii Expectedness ......................................................................................... 34
6.e Data Collection Procedures for Adverse Events and Unanticipated Problems 34
6.f Reporting Procedures ............................................................................. 35
6.g Adverse Event Reporting Period ............................................................. 36
6.h Post-study Adverse Event ....................................................................... 36

7.a Definitions of Outcomes .......................................................................... 36
   i Myocardial Reinfarction .......................................................................... 36
   ii Death and Cause of Death ...................................................................... 37
   iii Unscheduled Coronary Revascularization (unstaged) ......................... 37
   iv Readmission to Hospital, overall and for primary cardiac diagnosis ...... 37
   v Unstable Angina ...................................................................................... 37
   vi Congestive Heart Failure ........................................................................ 37
G1 CONFIDENTIALITY AND SECURITY ................................................................. 49
G2 TRAINING ........................................................................................................ 50
G3 CASE REPORT FORMS AND SOURCE DOCUMENTS ........................................ 50
G4 RECORDS RETENTION ..................................................................................... 51
G5 PERFORMANCE MONITORING ........................................................................ 51

H STUDY MONITORING, AUDITING, AND INSPECTING ....................................... 51
H1 STUDY MONITORING PLAN ............................................................................. 51
H2 AUDITING AND INSPECTING ........................................................................... 51

I STUDY ADMINISTRATION .................................................................................. 52
I1 ORGANIZATION AND PARTICIPATING CENTERS ............................................ 52
  1.a Clinical Coordinating Center ........................................................................ 52
  1.b Data Coordinating Center ............................................................................ 52
  1.c Clinical Consortium ..................................................................................... 53
I2 FUNDING SOURCE AND CONFLICTS OF INTEREST ................................... 53
I3 COMMITTEES ..................................................................................................... 53
  3.a Steering Committee .................................................................................... 53
  3.b Operations Committee ................................................................................ 54
  3.c Executive Committee .................................................................................. 54
  3.d Clinical Events Committee ......................................................................... 54
I4 SUBJECT STIPENDS OR PAYMENTS .............................................................. 54
I5 STUDY TIMETABLE ........................................................................................... 55

J PUBLICATION PLAN ......................................................................................... 56

Version 6.1
Introduction

A1 Statement of Compliance

The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46), and the NIH Terms of Award. The Principal Investigator will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.

I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments.

Principal Investigator: Jeffrey L Carson, MD
Print/Type Name

Signed: __________________________ Date: ____________
Signature
A2 Study Abstract

Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in most clinical settings. However, a low oxygen carrying capacity from moderate anemia may be deleterious in patients with cardiac ischemia. The potential for harm associated with anemia in patients with acute symptomatic coronary disease is supported by pathophysiological data that maintaining higher hemoglobin levels could benefit the ischemic heart by increasing oxygen delivery. Systematic reviews of clinical trials evaluating transfusion strategies in patients with known ischemic heart disease document the absence of high quality data, which has resulted in an ongoing controversy. The lack of high quality evidence to guide transfusions in patients with acute myocardial infarction has been cited in several major guidelines as well as by an NIH expert panel.

This multicenter trial, the Myocardial Ischemia and Transfusion (MINT) trial, randomly allocates 3500 patients with acute myocardial infarction and a hemoglobin concentration less than 10 g/dL to be treated either according to a liberal or restrictive blood transfusion strategy. Patients assigned to the liberal transfusion strategy receive one unit of packed red blood cells following randomization and enough blood to raise the hemoglobin concentration to 10 g/dL or above any time a concentration less than 10 g/dL is detected. Patients assigned to the restrictive transfusion strategy are permitted to receive a transfusion if the hemoglobin concentration falls below 8 g/dL or if angina symptoms clearly related to the anemia occur and are not controlled with anti-anginal medications. Only enough blood is given to reach a hemoglobin concentration of 8 g/dL or relieve the symptoms. Transfusion is strongly recommended if the hemoglobin concentration falls below 7 g/dL.

The transfusion protocol is followed during the index hospitalization (up to 30 days). Each patient is contacted at 30 days for a comprehensive follow-up for assessment of several relevant clinical outcomes. Patients are contacted again at 180 days to ascertain vital status for assessment of six-month mortality.

A3 Primary Hypothesis

The primary hypothesis is that among patients with an acute myocardial infarction and a hemoglobin concentration less than 10 g/dL, a liberal transfusion strategy with a threshold of 10 g/dL reduces the rate of the composite outcome of all-cause mortality or recurrent nonfatal acute myocardial infarction through 30 days following randomization compared to a restrictive transfusion strategy with a threshold of 7 to 8 g/dL.
A4  Purpose of the Study Protocol

The purpose of the trial is to assess red blood cell transfusion strategies that are currently used in clinical practice and important medical events. Red blood cells are a limited and expensive medical therapy. Physicians frequently transfuse patients to maintain specific (and often differing) hemoglobin levels, despite the lack of evidence supporting the strategy. The study results, which will determine the benefit (or risk) of a liberal transfusion strategy, will influence the allocation of red blood cells worldwide.
A5 Schematic of Study Design

Identify MI Patients

Hemoglobin level < 10 g/dL

Randomize

Liberal Transfusion    Restrictive Transfusion

In hospital followup up to 30 days
Follow Hgb levels and transfuse as per protocol. Obtain troponin, ECGs, and clinical followup

Followup at 30 days

Followup at 6 months
A6 Key Roles

Principal Investigator, Clinical Coordinating Center and Study Chair

Jeffrey L. Carson, MD
Provost, Rutgers Biomedical Health Sciences
Rutgers Robert Wood Johnson Medical School
125 Paterson Street
New Brunswick, New Jersey 08901
Telephone: 732-235-7122
FAX: 732-235-7144
Email: jeffrey.carson@rutgers.edu

Principal Investigator, Data Coordinating Center

Maria Mori Brooks, PhD
Professor of Epidemiology
University of Pittsburgh
Graduate School of Public Health
A530 Crabtree Hall / 130 DeSoto Street
Pittsburgh, PA 15261
Telephone: (412) 624-1618
FAX: (412) 383-5891
Email: mbrooks@pitt.edu

Project Scientist

Simone Glynn MD, MSc, MPH
Branch Chief
Blood Epidemiology and Clinical Therapeutics Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Tel: 301-435-0065
Fax: 301-480-0867
Email: glynnsa@nhlbi.nih.gov

Project Officer

Pablo Cure, MD, MPH
Program Officer
Blood Epidemiology and Clinical Therapeutics Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute, NIH
6701 Rockledge Drive, Room 9163
Bethesda, MD 20892-7950
Tel: +1-301-451-7431 Email: pablo.cure@nih.gov

Version 6.1
**B Background**

**B1 Prior Literature and Studies**

Blood transfusion is a common medical intervention. In the United States, more than 16 million red blood cell units are transfused annually to 3.4 million patients. Worldwide 108 million units of blood are collected per year. Of all transfusions, approximately 25% of all red cells transfused are given to patients with a primary diagnosis of cardiac disease and 8% of all cardiology admissions are transfused with RBCs. The economic ramifications of this frequent intervention are significant. The latest estimates of the cost of a red blood cell unit range from $522 to $1183 (mean, $761±$294). The safety of transfusion with respect to transmission of infectious agents has increased greatly throughout the past two decades, and complications are rare. (6, 7)

**Anemia and Cardiac Disease:** Generating evidence to guide transfusion threshold decisions in patients with myocardial infarction is especially important because coronary artery disease is so common. Anemia is present frequently in this setting, and is associated with increased mortality. A study of 44,242 patients with non-ST segment elevation myocardial infarction from 400 US hospitals found 22.2% of patients had a hematocrit <30% (Hgb ≤10 g/dL). In-hospital mortality was 10.4% in patients with Hgb <10 g/dL compared to 2.7% in patients with Hgb >10 g/dL. In a second study involving 17,676 patients with acute myocardial infarction, hospital-acquired anemia (Hgb <11 g/dL) developed in 20.1% of patients during the hospitalization. Patients with Hgb <9 g/dL had a strong association with mortality (odds ratio=3.39). The mechanism of early mortality in patients with acute cardiac injury and anemia may be related to a low ischemic threshold leading to myocardial injury, congestive heart failure and ventricular arrhythmia.

Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in most clinical settings with the possible exception of patients with acute coronary syndrome. Most reviews and guidelines define a restrictive transfusion strategy as the administration of red cells once hemoglobin falls below either 7 or 8 g/dL while a liberal strategy is most often suggested as a transfusion trigger of 10 g/dL.

**Pathophysiology:** The AABB (formerly called the American Association of Blood Banks) guidelines on Red Blood Cell
Transfusion recently recommended the use of restrictive transfusion triggers in most patients with the exception of those with an acute coronary syndrome. (15, 16) Their rationale – in the absence of randomized trial evidence – was the large body of basic physiology and observational data would suggest that a restrictive strategy may be deleterious. This is because oxygen delivery to the myocardium is flow dependent since the heart extracts a high percentage of oxygen. Therefore, myocardial ischemia may be precipitated or worsened by low hemoglobin concentrations, especially in patients with coronary stenosis or active plaques. Studies performed in canines suggest a decreased ability to tolerate anemia in the presence of coronary artery disease. (17-19) Electrocardiographic changes consistent with ischemia are seen at hemoglobin concentration below 5 g/dL in normal animals but at 7-10 g/dL with experimentally induced coronary artery disease.

Data from patients who decline blood transfusion for religious reasons were congruent with animal data. In a retrospective cohort study that included 1,958 adult surgical patients who declined transfusion for religious reasons and found a significant interaction between underlying cardiovascular disease and preoperative Hgb level with respect to death (p=0.03). (20) In patients with underlying cardiovascular disease the adjusted odds of postoperative death began to rise sharply at Hgb level ≤10 g/dL while in patients without underlying cardiovascular disease there was a more subtle rate of increasing risk below 10 g/dL (see Figure 1). This study does not address whether transfusion would improve outcome.

Transfusion could be harmful by several possible pathophysiological mechanisms. Transfusion has been shown to increase platelet reactivity and increase procoagulant proteins. (21) Stored red blood cells take time to replenish 2, 3 DPG levels impairing release of oxygen (22, 23) and have low levels of nitrous oxide impairing oxygen delivery and vasodilation. (24) The membranes of stored red blood cells may become deformed and plug microvascular vessels. (25, 26)

**Systematic Reviews, Observational Studies:** We have identified or conducted systematic reviews of both observational studies and clinical trials. As expected, a systematic review of observational studies in all patients found that blood transfusion was associated with increased mortality and morbidity. (27) Two recent systematic reviews focusing specifically on patients with myocardial infarction identified 10 studies (9 observational and 1 pilot trial) reporting the effects of transfusions on mortality. (28, 29) Nearly all observational studies demonstrated an association between transfusion and higher mortality. The one exception was in a large study using Medicare billing data in 79,000 patients with acute myocardial infarction. (30) Transfusion was associated with a lower risk of death.
when patients had an admission hematocrit below 0.33 (equal to a hemoglobin concentration of 11 g/dL) (odds ratio= 0.69; 95% CI, 0.53-0.89) and relationship between transfusion and better outcomes increased as the hematocrit fell. Indeed, based on subgroup analyses, the authors of the systematic review report that the adverse effects of transfusion appear to be mitigated in patients with a hematocrit less than 0.33. Unfortunately, observational studies cannot be used to evaluate the effect of red blood cell transfusion since the use of blood transfusion is a marker for illness burden.(29, 31) Thus, no matter how refined the adjustment is for differences in illness burden, it is difficult, if not impossible, to completely adjust for differences between patients receiving and not receiving blood transfusion.

**Systematic Reviews, Clinical Trials:** We have performed a systematic review of clinical trials evaluating transfusion triggers in a variety of populations that were published in the Cochrane database(32) and JAMA.(33) We have updated the review (34) and found that compared with higher hemoglobin transfusion thresholds (~10 g/dL), a hemoglobin transfusion threshold of 7 or 8 g/dL is associated with fewer red blood cell units transfused (mean difference, -1.22 units per patient), without adverse associations with mortality, cardiac morbidity, functional recovery, or length of hospital stay. The relative risk for the association of restrictive versus liberal transfusion on 30-day all-cause mortality was 0.99 (95% CI, 0.82 to 1.20).

A recent meta-analysis of 11 selected trials enrolling patients with cardiovascular disease (including data obtained from authors from four trials) was recently reported. The risk ratio for the association between transfusion thresholds and 30-day mortality was 1.15 (95% confidence interval 0.88 to 1.50), but the risk of acute coronary syndrome in patients in the restrictive compared with liberal transfusion group was increased in nine trials (risk ratio 1.78, 95% confidence interval 1.18 to 2.70).(35)

**Clinical Trials in Acute Coronary Syndrome:** Our systematic review identified two pilot clinical trials that included patients suffering an acute coronary syndrome. The first was a small pilot trial including 45 patients with acute myocardial infarction.(36) Patients with hematocrit less than 30% were randomly allocated to a liberal (hematocrit <30%) versus restrictive (hematocrit < 24%) transfusion threshold. The primary clinical safety measurement of in-hospital death, recurrent myocardial infarction, or new or worsening congestive heart failure occurred in 8 patients in the liberal arm and 3 in the restrictive arm (p< 0.046). There were 2 deaths in restrictive group and 1 death in the liberal group. The authors concluded a definitive trial was urgently needed.
In contrast, the MINT pilot enrolled 110 patients and found the pre-defined primary outcome of death, myocardial infarction, or unscheduled revascularization within 30 days occurred in 6 patients (10.9%) in the liberal-transfusion strategy and 14 (25.5%) in the restrictive-transfusion strategy \( p=0.054 \).

Death at 30 days was less frequent with liberal transfusion 1 (1.8%) compared to restrictive transfusion 7 (13.0%); \( p=0.032 \).

Overall, there were 2 deaths in the liberal transfusion strategy and 9 deaths in the restrictive transfusion strategy (relative risk= 3.74, 95% CI 0.80-17.49; \( p=0.09 \)) when the two trials in acute coronary syndrome are combined.

**Other Trials (37) with Signal of Harm from Restrictive Transfusion:** The two most recently published trials also found a higher mortality in patients in the restrictive transfusion group in patients with ischemic heart disease. The Titre2 trial contrasted liberal transfusion (9 g/dL) and restrictive transfusion (7.5 g/dL) in postoperative patients undergoing cardiac surgery. The short-term outcomes were comparable between the transfusion strategies, but at 90 days follow-up, overall mortality was higher in the restrictive transfusion strategy than the liberal transfusion strategy (hazard ratio=1.64; 95% confidence interval, 1.00 to 2.67, \( p=0.045 \)). In a cluster randomized trial in 939 patients with GI bleeding, the mortality was trending higher in subgroup of patients with underlying ischemic heart disease; liberal transfusion strategy was 3% and in the restrictive transfusion strategy was 12% (difference =10.7%; 95% confidence intervals -9.8 to 31.2; interaction \( p=0.11 \))

**Variation in Transfusion and Guidelines:** The systematic reviews of observational studies and randomized trials evaluating the impact of anemia and transfusion highlight the lack of any study with sufficient numbers of patients to guide clinical care. All of this uncertainty has helped fuel significant practice variation. Two large studies in 44,242 patients with non-ST segment elevation myocardial infarction from 400 US hospitals(9) and 17,676 patients with acute myocardial infarction demonstrate substantial variation in transfusion.(10) Similar variation as observed in over 2000 hospitalized patients from the California Kaiser Permanente Health System. A significant proportion of patients had transfusion thresholds at every cut-off from 7 to 10 g/dL – again indicating important clinical uncertainty.

The variation in transfusion practice may further be exacerbated by the great variability in the transfusion guideline recommendations. While all conclude that there are too few high quality studies, recommendations vary widely among organizations. The American Red Cross, AABB, British
Committee for Standards in Haematology were not able to recommend a course of action,\textsuperscript{(38, 39)} the American College of Physicians recommends 7-8 g/dL in patients with heart disease but is silent in acute coronary syndrome patients;\textsuperscript{(40)} the American College of Cardiology/American Heart Association suggests avoidance of transfusion unless hemoglobin less than 8 g/dL\textsuperscript{(41, 42)}; and the European Society of Cardiology recommends transfusion only in case of compromised hemodynamic status and hemoglobin less than 7 g/dL.\textsuperscript{(43)} The recently published guidelines from the AABB concluded that there was insufficient evidence in patients with acute MI and did not provide a specific recommendation,\textsuperscript{(44)} while the UK National Clinical Guidelines Centre recommended transfusion at 8 g/dL\textsuperscript{(45)}. Given the lack of high quality evidence to guide transfusion in patients with acute myocardial infarction, it is not surprising that there is variation in recommendations emanating from different organizations.

**B2 Rationale for this Study: Equipoise**

Every day, clinicians encounter anemic patients who have acute ischemic heart disease where a decision to transfuse must be made. However, clinicians do not know what to do because: 1) Observational studies and randomized trials have come to different conclusions and are flawed; 2) Pathophysiological arguments can be made for liberal and restrictive strategies; 3) Some clinical trials in other settings suggest a restrictive transfusion approach is safe but other trials signal the possibility of reduced mortality with liberal transfusion in patients with cardiac disease; 4) Guidelines provide conflicting advice. This has led to practice variation\textsuperscript{(9, 46)} and confusion in the clinical community with no clear guidance on when to transfuse. Thus, the NHLBI State of the Science expert panel concluded in March 2015 “equipoise for transfusion thresholds persists in patients with ischemic heart disease.”\textsuperscript{(47)} The ACC/AHA guidelines for management of STEMI concluded, “the optimal hemoglobin level in the transfused patient is not known.”\textsuperscript{(41, 42)} Furthermore, the recently published guidelines by the AABB identified acute coronary syndrome as clinical setting where the evidence is “judged to be insufficient” to recommend transfusion threshold.\textsuperscript{(16)} Based on these findings and existing data there clearly is equipoise. For all these reasons, a high quality randomized trial to guide transfusion is urgently needed to answer this clinically relevant question.
C Study Objectives

C1 Primary Aim

The primary aim is to determine whether a liberal transfusion strategy with a threshold of 10 g/dL reduces the composite outcome of all-cause mortality or nonfatal myocardial reinfarction through 30 days following randomization, compared to a restrictive transfusion strategy with a threshold of 7 to 8 g/dL among patients with an acute myocardial infarction and a hemoglobin concentration less than 10 g/dL.

C2 Secondary Aims

1) To determine whether a liberal (10g/dL) transfusion strategy reduces all-cause mortality within 30 days, compared to a restrictive transfusion strategy.

2) To determine whether a liberal (10g/dL) transfusion strategy reduces myocardial reinfarction within 30 days, compared to a restrictive transfusion strategy.

3) To determine whether a liberal (10g/dL) transfusion strategy reduces the composite outcome of all-cause mortality, nonfatal myocardial reinfarction, ischemia driven unscheduled coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), or readmission to the hospital for ischemic cardiac diagnosis within 30 days, compared to a restrictive transfusion strategy.

C3 Tertiary Aims

1) To determine whether a liberal (10g/dL) transfusion strategy reduces all-cause mortality, nonfatal myocardial reinfarction, or unstable angina (i.e. acute coronary syndrome) within 30 days, compared to a restrictive transfusion strategy.

2) To determine whether a liberal (10g/dL) transfusion strategy reduces ischemia driven unscheduled coronary revascularization within 30-days compared to a restrictive strategy.

3) To determine whether a liberal (10g/dL) transfusion strategy reduces unscheduled readmission to hospital for ischemic cardiac diagnosis within 30 days, compared to a restrictive strategy.
4) To determine whether a liberal (10g/dL) transfusion strategy increases congestive heart failure within 30 days, compared to a restrictive transfusion strategy.

5) To determine whether a liberal (10g/dL) transfusion strategy reduces unscheduled readmission to hospital for any reason within 30 days, compared to a restrictive strategy.

6) To determine whether a liberal (10g/dL) transfusion strategy increases each of the individual thrombotic/hemorrhagic outcomes of stroke, pulmonary embolism or deep venous thrombosis, and bleeding within 30 days, compared to a restrictive strategy.

7) To determine whether a liberal (10g/dL) transfusion strategy increases each of the individual infectious outcomes of pneumonia, blood stream, and urinary tract within 30 days, compared to a restrictive strategy.

8) To determine whether a liberal (10g/dL) transfusion strategy reduces each of the individual in-hospital outcomes of length of hospital stay post randomization and number of days in intensive care unit, compared to a restrictive strategy.

9) To determine whether a liberal (10g/dL) transfusion strategy increases patient reported quality of life using the EuroQol questionnaire (EQ-5D) at 30 days compared to a restrictive strategy.

10) To determine whether a liberal (10g/dL) transfusion strategy reduces all-cause mortality at 6-months following randomization, compared to a restrictive strategy.

C4 Rationale for the Selection of Outcome Measures

The study outcomes assess the clinically important benefits and harms of transfusion and anemia in vulnerable individuals with compromised myocardium. Blood transfusions may decrease ischemic injury and improve myocardial performance by improving oxygen delivery to the myocardium in high-risk patients. However, transfusions may also harm patients. Blood transfusions acutely increase blood volume in patients who may not adapt rapidly enough resulting in increased rates of pulmonary edema and heart failure. The increased blood volume could also lead to higher risk of bleeding from increased intravascular pressure. Blood transfusion is also associated with immunosuppression and may lead to infection. In addition, laboratory data suggest that transfusions may not enhance oxygen delivery and may be associated with increased platelet aggregation.
If transfusion to maintain the hemoglobin concentration >10 g/dL does mitigate the clinical consequences of anemia in ischemic cardiac injury, there will be a reduction of mortality and reinfarction. Higher hemoglobin concentrations might also reduce other sequelae of decreased oxygen delivery to the myocardium; unscheduled coronary revascularization, hospital readmission for ischemic symptoms, unstable angina, and cardiovascular mortality.

On the other hand, if transfusion results in clinically important fluid overload, immunosuppression, increased viscosity, and inflammation there will be an increase in congestive heart failure, infection, bleeding, stroke, and pulmonary embolism or deep venous thrombosis. Each of these may contribute to death or reinfarction.

Higher hemoglobin levels may also be associated with a more positive feeling of well-being and a better perceived quality of life as measured by the EQ-5D.

Outcomes are assessed at 30 days since blood transfusion will have its maximum effect within this time period. Mortality will also be assessed at 6 months to determine if early effects of blood transfusion persist.

**D Study Design**

**D1 Overview or Design Summary**

This is a randomized, unblinded, two group multicenter clinical trial. Eligible study patients are randomized to receive either the liberal or the restrictive transfusion strategy. Transfusion strategy assignment is not blinded. The transfusion protocol is followed during the Index hospitalization (for up to 30 days). Each patient will be contacted at 30 days to ascertain study outcomes and at 6 months when vital status will be verified. The 30-day and 6-month follow-ups will be administered by telephone, but the follow-up questions could be administered in person, for example, if the patient is in the hospital during the follow-up window. During the 30-day follow-up, readmissions to the hospital that have occurred within the 30 days are identified and medical records will be obtained. The Clinical Events Committee, masked to treatment allocation, will adjudicate occurrences of myocardial infarction within the 30-day window.

Each of the transfusion strategies in this trial is routinely used in current medical practice. Study patients will be followed while they are in the hospital (for up to 30 days) during which time
hemoglobin levels, cardiac biomarker of necrosis levels, electrocardiograms, and number of units of red blood cell transfusions administered will be collected.

The transfusion strategies will be compared for differences in mortality, cardiac events and other important morbidity, hospital re-admissions, and patient perceived quality of life.

The goal of this study is to determine whether a liberal transfusion strategy is superior to a restrictive strategy in anemic patients with acute myocardial infarction.

D2 Subject Selection and Withdrawal

2.a Inclusion Criteria

The eligible study population includes patients who meet all of the following criteria: 1) 18 years of age or older; 2) with either ST segment elevation myocardial infarction or Non ST segment elevation myocardial infarction consistent with the 3rd Universal Definition of Myocardial Infarction criteria (37) that occurs on admission or during the index hospitalization, and 3) with a hemoglobin concentration less than 10 g/dL at the time of random allocation.

To simplify the diagnosis of acute myocardial infarction, we will require a rise in cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the upper reference limit of normal of the hospital. We anticipate (and will confirm) that the hospital upper limit of normal for troponin will be equivalent to or above the 99th percentile upper reference at all hospitals.

In addition to evidence of myocardial necrosis, we require patients to have at least one of the following: (1) symptoms of ischemia; (2) new/presumed new ST segment or T wave (ST-T) changes or new left bundle branch block (LBBB); (3) development of pathological Q waves; (4) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; and/or (5) identification of an intracoronary thrombus by angiography. (37) We will include patients with Type 1 (i.e., spontaneous MI presumably related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries, leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis), Type 2 (i.e., secondary to an ischemic imbalance such that myocardial injury with necrosis occurs due to myocardial oxygen supply and/or demand mismatch), Type 4b (i.e., stent thrombosis at angiography), and Type 4c (i.e., severe in-stent restenosis without evidence of thrombus).
2.a Exclusion Criteria

Patients will be excluded if any of the following criteria are met: 1) uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood; 2) decline blood transfusion; 3) scheduled for cardiac surgery during the current admission; 4) are receiving only palliative treatment; 5) if known that follow-up will not be possible at 30 days; 6) if previously participated in MINT or 7) if currently enrolled in a competing study that interferes with the intervention or follow-up of MINT or enrolled in a competing study that has not been approved by the local IRB.

Patients who have had an episode of uncontrolled bleeding may be enrolled later if the hemoglobin remains below 10 g/dL, they are no longer actively bleeding, and they are otherwise still eligible.

2.b Ethical Considerations

Both transfusion strategies assessed in this trial are widely used in clinical practice. There is uncertainty about which strategy is better, and therefore there is clinical equipoise to conduct this study. Thus, there are no clinical risks to patients above those of usual practice. There are no other alternative treatments.

At the time consent is obtained, the clinical site study staff will also request the names and contact information of two additional individuals who may be contacted in the event study staff are not able to reach the patient directly at the follow-up time points. This will minimize loss to follow-up. This information will be retained at the clinical site and destroyed at the end of the trial.

2.c Randomization Method and Blinding

The Data Coordinating Center (DCC) will prepare the randomization schedules. Allocation of the transfusion intervention strategies will be in a 1:1 ratio. Given the diverse patient mix among participating clinical sites, the randomization will be stratified by clinical site, and a permuted block design with random block sizes will be used to balance treatment assignments within each clinical site.

Study patients and physicians caring for the patient cannot be masked to treatment assignment (i.e., administration of red blood cell transfusion). However, the central classification of the myocardial reinfarction component of the primary outcome is performed masked to assignment.
2.d Subject Recruitment Plans and Consent Process

The study recruits hospitalized patients diagnosed with acute myocardial infarction (Type 1, Type 2, Type 4b, or Type 4c). Prior to study initiation, each cardiologist at the clinical site will be personally contacted by the clinical site principal investigator or coordinator and permission will be sought to recruit patients who are eligible for the study. Patients of physicians who do not wish to participate in the trial will not be approached for recruitment.

Study staff will identify potential study patients, confirm that the physician agrees that the patient can be randomized into the study and approach the patient for consent. Surrogate consent, in accordance with local IRB rules, will be sought for each eligible patient who is not able to grant consent. A substantial number of patients eligible for this trial are likely to be critically ill, medicated, and/or cognitively impaired and unable to grant consent. It is essential that these patients be included as physicians routinely face the dilemma of whether or not they should be transfused.

2.e Risks and Benefits

In patients with heart disease, risks and benefits are considerably different than most other patient populations. Oxygen delivery to the myocardium is flow dependent since the heart extracts a high percentage of oxygen and myocardial ischemia may be precipitated or worsened by low hemoglobin concentrations, especially in patients with acute myocardial infarction. Anemia, if untreated may result in increased risks of further myocardial ischemia and injury. Transfusions, on the other hand, may result in increased risks of pulmonary edema and heart failure (Transfusion-Associated Circulatory Overload), from the significant amounts of volume given to patients with impaired ability of the heart to pump (systolic dysfunction) or ability to relax and fill (diastolic dysfunction). Other adverse effects of allogeneic blood transfusion were also a concern: immunologic (transfusion-related acute lung injury [TRALI]),(48) and transfusion-related immune modulation [TRIM] possibly leading to increased bacterial infections).(49) Thus, there is clinical equipoise because it is unclear whether the benefits of immediate correction of anemia with transfusion are outweighed by the potential side effects of transfusion.
2.f Early Withdrawal of Subjects from Transfusion Strategy and Trial Procedures

The study participant (i.e. patient) can be withdrawn from the transfusion strategy (liberal or restrictive transfusion allocation) at any time, either at the request of the treating physician or the patient themselves. The clinical site director may also withdraw a patient. Following the withdrawal, all transfusion decisions will be per treating physician. The patient or physician may also request withdrawal from any trial procedure or follow-up.

2.g When and How to Withdraw Subjects

There are few reasons why a patient or physician might want to withdraw from the trial. If the patient has an adverse effect from a prior transfusion or proves to be difficult to cross match, the physician or patient may choose to withdraw from the study. However, the most common reasons are likely to be patient’s preference not to participate in research or desire not to have extra blood tests or be contacted for follow-up. If a concern is raised and a request for withdrawal is made by the patient or the physician, study staff will confirm the issue (e.g., transfusion strategy, study required measurements and/or telephone follow-up) and try to address the concern. Study staff will be required to contact the MINT CCC PI to discuss the individual situation. If appropriate, the patient will be given the opportunity to refrain from the objectionable study procedure(s) and remain in the overall study. All efforts will be made to avoid a participant feeling unduly pressured to remain in the study. If no intermediate solution is acceptable to the patient and/or treating physician, the patient will be withdrawn from the study. The study staff will document the date of withdrawal, any known reasons for withdrawal and whether the patient will continue with any of the study procedures and/or follow-up. All treating physicians will be immediately notified of a withdrawal from the transfusion strategy (liberal or restrictive transfusion allocation).

2.h Data Collection and Follow-up for Withdrawn Subjects

At the time of withdrawal, the study staff will request permission to continue with data collection and follow-up through the 6-month study time window. However, the exact amount of follow-up performed will vary in accordance with the patients' authorization.
D3 Trial Transfusion Strategies

3.a Description

We are comparing two commonly used approaches to transfusion therapy, both of which can be considered as “standards of care.” For both strategies, blood must be administered one unit at a time followed by a hemoglobin measurement. The transfusion strategy will be followed throughout the index hospitalization up to 30 days, discharge, or death.

3.b Transfusion Strategies

Restrictive Transfusion Strategy: Patients randomized to the restrictive transfusion strategy will be permitted to receive a transfusion if the hemoglobin concentration falls below 8 g/dL and will be strongly recommended to receive transfusion if the hemoglobin concentration is below 7 g/dL. Transfusion is also permitted if angina symptoms (i.e., retrosternal chest discomfort, chest discomfort described as pressure or heaviness) that are thought by the clinician to be related to anemia occur and are not controlled with anti-anginal medications (sublingual nitroglycerin or equivalent therapy). Blood will be administered one unit at a time and enough blood given to increase the hemoglobin concentration above 7 to 8 g/dL or to relieve symptoms of uncontrolled angina.

Liberal Transfusion Strategy: Patients randomly allocated to the liberal transfusion strategy will receive one unit of packed red cells following randomization and will receive enough blood to raise the hemoglobin concentration to 10 g/dL or above any time the hemoglobin concentration is detected to be below 10 g/dL. A post transfusion hemoglobin measurement showing a hemoglobin level of at least 10 g/dL must be obtained.

A patient in either group may be transfused at any time without a hemoglobin level if the patient is actively bleeding (e.g., brisk gastrointestinal bleeding) and the physician believes an emergency transfusion is needed. A patient in either group with history of congestive heart failure or low ejection fraction may receive diuretics prior to or after transfusion.

3.c Rationale for Transfusion Thresholds

The restrictive transfusion group reflects many current guidelines (including European guidelines)(43, 50). A blood transfusion will be permitted in the restrictive group if the hemoglobin concentration is less than 8 g/dL. Discussions with many cardiologists suggested that many clinicians are not
comfortable with a threshold as low as 7 g/dL (as used in TRICC); however, individual clinicians may choose to use a threshold of less than 7 g/dL to trigger transfusions. Patients may be transfused for signs or symptoms when the clinician believes it is necessary although this did not occur in the pilot trial and was uncommon in the FOCUS trial which also incorporated symptoms in the restrictive transfusion protocol.

In the liberal transfusion group, a threshold of less than 10 g/dL was chosen because oxygen delivery to the myocardium is flow dependent and myocardial ischemia may be precipitated or worsened by low hemoglobin concentrations in patients with coronary stenosis or active plaques. Studies performed in canines found electrocardiographic changes consistent with ischemia as high as 10 g/dL with experimentally induced coronary artery disease. Data from patients who decline blood transfusion for religious reasons were congruent with animal data and found the odds of death rose as the hemoglobin fell below 10 g/dL.

3.d Method for Assigning Subjects to Treatment Groups

Clinical site staff will obtain the randomly assigned transfusion strategy for each eligible consented patient using the MINT website. The randomization system will be available via a secure area of the MINT project website with access restricted to those clinical site personnel with permission to randomize patients. Those who are certified to use the randomization system will be trained to adhere to a strict randomization protocol. In particular, the clinical site personnel must confirm the patient’s eligibility status in the system before a transfusion strategy assignment is provided. If the web-based randomization system is not accessible, clinical site personnel will be instructed to follow back-up procedures in order to ensure that the clinical centers are able to randomize patient 24/7.

3.e Preparation and Administration of Red Blood Cell Transfusions

All red blood cell units are maintained and ordered through the hospital blood bank. The storage solution and storage time will be at the discretion of the blood bank, but only leukoreduced red blood cell transfusion will be used. The transfusions are administered by hospital staff in accordance with hospital policy. Study staff will alert the nursing and medical staff to the assigned transfusion strategy each time a new patient has been enrolled in the study. Treating staff will order (or not order) red cell transfusions in accordance with the protocol.
3.1 Subject Compliance Monitoring

There are two primary site based mechanisms to ensure adherence to the assigned transfusion strategy: 1) study staff review of the medical record and, if necessary, direct discussion with the treating physicians and, 2) direct assistance from the blood bank.

The clinical site is to obtain a daily hemoglobin level for each randomized patient for the first three days following randomization (or through hospital discharge, if sooner). Additional hemoglobin levels are measured as clinically indicated. Study staff will closely monitor each patient to ensure that each of the required hemoglobin levels are drawn, review the results, and confirm that the transfusions have been ordered (or not ordered) in accordance with the transfusion assignment. If there is a hemoglobin value that should trigger a transfusion and none is ordered or, as the alternative, a transfusion ordered without a hemoglobin value to trigger the transfusion, study staff will discuss the case with the treating physician. Likewise, if a required hemoglobin level has not been ordered, the study staff will alert the physician. The required hemoglobin measurements are of primary importance to verify that patients in the liberal strategy maintain a level of at least 10 g/dL.

The clinical site will also request assistance from the blood bank to help prevent protocol violations in the restrictive strategy. Study staff will notify the blood bank each time a patient is assigned to the restrictive strategy and request notification prior to the release of any red blood cell transfusions that are ordered. The study staff will then review the medical record to verify that the transfusion is in accordance with the protocol. If administration of blood is a violation of the protocol, study staff will contact the ordering physician to discuss transfusion plans and to clarify the study protocol. However, study staff do not approve or disapprove the transfusion. The final decision on the transfusion is always the treating physician’s.

Study wide, the DCC will centrally monitor transfusions and hemoglobin levels on an ongoing basis. Transfusion rates for each strategy will be measured overall and by clinical site. Specifically, the DCC will identify instances when 1) patients randomized to the liberal strategy do not receive a transfusion, 2) patients randomized to the liberal strategy are discharged with a hemoglobin level < 10 g/dL and, 3) patients randomized to the restrictive strategy without anginal symptoms and a hemoglobin level ≥ 8 g/dL receive a transfusion. Reports of the protocol violations will be prepared by the DCC. The Clinical Coordinating Center (CCC) will review these reports and discuss as necessary with the clinical sites.
3.g  Prior and Concomitant Therapy

Transfusion prior to randomization is at the discretion of the clinicians. An otherwise eligible patient may be randomized as long as the hemoglobin level is <10g/dL, regardless of prior transfusions at the time of randomization. Once the patient has been randomized all red cell transfusions are administered per the study protocol. The protocol will not control the administration of other blood products including platelets or fresh frozen plasma. Similarly, it will not mandate specific medical or procedural treatments to manage these patients.

3.h  Blinding of Study Intervention

Due to the nature of the interventions, study patients and physicians caring for the patients cannot be blinded to transfusion assignment. However, transfusion strategy assignment will be concealed during the central classification of the myocardial reinfarction component of the primary outcome.

E  Study Procedures

E1 Screening for Eligibility

Several approaches to screening for study patients will be used. Study staff will review the results of all troponin levels daily. Medical records for patients with values above the upper reference limit of normal are reviewed and assessed for eligibility. Study staff will screen all admissions to the cardiac care unit, and scheduled for cardiac catheterization. The physician of each eligible patient with a hemoglobin level <10 g/dL will be contacted to confirm that the patient can be entered into the trial, and consent will be sought. Study staff will follow otherwise eligible patients with hemoglobin levels ≥ 10 g/dL and consent the patient if the hemoglobin level drops to the entry level.

E2 Schedule of Measurements

Each randomized patient is required to have hemoglobin levels, troponin levels, and electrocardiogram readings at specified time points (while in the hospital). The blood samples will normally be drawn with the daily morning blood phlebotomy.

The required time points for hemoglobin levels are: 1) within 24 hours prior to randomization (eligibility hemoglobin level), 2) day 1 post randomization, 3) day 2 post randomization, 4) day 3 post randomization.
The required time points for the troponin levels are: 1) within 24 hours prior to randomization, 2) 12 hours following randomization, 3) day 1 post randomization, 4) day 2 post randomization, 5) day 3 post randomization.

The required time points for the ECGs are: 1) within 24 hours prior to randomization, 2) day 1 post randomization, 3) day 2 post randomization, 4) day 3 post randomization.

A listing of the types of data elements that will be collected at each time point is presented in Appendix 1.

**E3 In-hospital Follow-up**

Study staff will review the medical records and follow participants during the hospitalization, for up to 30 days post randomization. They will carefully follow and document hemoglobin levels and transfusion status to assure that the transfusion protocol is being followed. In addition, during the first 3 days following randomization they will confirm that each of the required cardiac biomarkers for necrosis, hemoglobin levels, and electrocardiograms has been ordered and the results are recorded.

At 30 days post randomization, or hospital discharge if sooner, the study staff will complete and submit all study data related to the hospitalization including baseline health status, laboratory results, post randomization events and copies of all electrocardiograms performed.

**E4 Follow-up at 30 Days**

Study staff at the clinical sites will contact each patient at 30 days following randomization. In general, the 30-day follow-up will be administered by telephone, but the follow-up questions could be administered in person. The follow-up interview will include questions about the patient’s health and quality of life during the follow-up interval and will determine if there have been any re-admissions to a hospital within 30 days of randomization. Local site staff will obtain the hospital records for each re-admission.

There will be a 30-day window (from 30 days to 60 days following randomization) for study staff to obtain the 30-day follow-up information. In the event they are not able to contact the patient directly, they will try to reach the alternate contacts that have been provided, and a letter will be sent to the patient if needed.
E5 Follow-up at 6 Months

Study staff at the clinical sites will perform a final follow-up contact at 6 months following randomization to determine the patient's vital status. There will be a 30-day window (from 180 days to 210 days following randomization) to obtain the 6-month information. In the event that study staff are not able to contact the patient at the 6-month time point, they will follow the same procedure outlined at the 30-day follow-up.

E6 Safety and Adverse Events

6.a Safety and Compliance Monitoring

The DCC will monitor key aspects of protocol compliance, and reports will be developed and disseminated to monitor the ongoing progress of the study. Protocol safety and compliance reports will include enrollment of ineligible patients, follow-up data collection outside of protocol-defined windows, deviations from the protocol, and adherence to established adverse event reporting and event adjudication procedures. Reports will be provided to the CCC, the Steering Committee, and the DSMB on a systematic basis.

6.b Medical Monitoring

The DCC is responsible for tracking the Serious Adverse Events (SAEs) reported by clinical sites in the MINT trial. The DCC will track the time for each step of the process to ensure that turnaround times adhere to acceptable reporting practices specified by the FDA and NIH. The current reporting guidelines from NHLBI (https://www.nhlbi.nih.gov/research/funding/human-subjects/adverse-event) will be followed, and the timelines are included in Appendix 2.

i Investigator Only

The clinical site will submit a SAE form to the DCC for unexpected serious adverse events occurring within 30 days of randomization and for unexpected deaths occurring within 6 months of randomization. The clinical sites are responsible for notifying their local Institutional Review Board. Expected SAEs will be reported on the standard MINT in-hospital and follow-up data collection forms.
ii Independent Expert to Monitor

The DCC will notify the MINT Medical Safety Officer of unexpected SAEs submitted by a clinical site and make the relevant information available to the officer. The Medical Safety Officer will determine a) the severity of the event, b) the unexpectedness, and c) the relatedness to the study protocol. In accordance with safety reporting regulations, all SAEs that are determined by the Medical Safety Officer to be both unexpected and possibly, probably or definitely related to the study protocol will be subject to expedited reporting to the Data and Safety Monitoring Board (DSMB), NIH, and any other oversight entities as appropriate. The NIH Project Officer and the DSMB chairperson will review these documents and may decide to convene the DSMB to discuss issues related to monitoring such events.

iii Independent Data and Safety Monitoring Board

An external Data and Safety Monitoring Board (DSMB) consisting of members appointed by the National Heart, Lung, and Blood Institute (NHLBI) will monitor the study, advise the NIH Program Office and provide input to the Steering Committee. The MINT DSMB will include experts in cardiology, transfusion medicine, biostatistics and ethics. The DSMB will review the study protocol and provide NHLBI with recommendations including whether the protocol and patient recruitment can be initiated. NHLBI will approve the study protocol based on the DSMB recommendations before patient recruitment is initiated. Throughout the course of the trial, the Data and Safety Monitoring Board (DSMB) will review recruitment, retention, data completeness, and protocol deviations on a semi-annual basis and will provide recommendations to NHLBI.

Adverse events will be monitored in four distinct ways: 1) the DSMB will review all reported adverse events and monitor the incidence rates of adverse events on a semi-annual basis, 2) the expedited review of unexpected Serious Adverse Events (SAE) that are related to the MINT protocol and unanticipated problems (UP), 3) all study outcomes will be evaluated by assigned treatment group on semi-annual basis, and 4) a formal statistical interim monitoring of the efficacy of the primary outcome by assigned treatment group will be performed on an annual basis. If unexpected safety concerns arise from the trial data or from external research or literature, safety data will be examined on an ad hoc basis. The DCC will work with the NIH and with the DSMB to make certain that the board members have sufficient information to comprehensively monitor patient safety throughout the MINT trial. The DSMB may advise early termination of the trial for safety reasons or make other recommendations regarding modifications to the protocol.
In order to ensure that the MINT trial has adequate power to test its primary aims, the DSMB will review an interim sample size/power analysis after half of the patients complete the 30-day follow-up. Revised sample size estimates will be calculated based on the observed overall event rate (i.e. the two transfusion groups combined) and the proposed power and effect size.

6.c Definitions of Adverse Events

An adverse event is defined as an untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with a person’s participation in the research, whether or not considered related to a person’s participation in the research. A Serious Adverse Event (SAE) is defined as an adverse event that meets any of the following criteria:

- results in death;
- is life-threatening i.e. places a participant at immediate risk of death from the event as it occurred;
- requires inpatient hospitalization or prolongation of existing hospitalization;
- results in a persistent or significant disability/incapacity;
- results in a congenital anomaly/birth defect; OR
- any other adverse event that, based upon appropriate medical judgment, may jeopardize the participant’s health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.

An Unanticipated Problem (UP) is defined as any incident, experience, or outcome that meets all of the following criteria:

- Unexpected in terms of nature, severity, or frequency, taking protocol research procedures and participation population characteristics into consideration.
- Related or possibly related to a person’s participation in the research.
- Places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.
6.d Classification of Events

i Severity

The severity of the adverse event refers to the intensity of an event and is categorized as 1) Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, 2) Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living, 3) Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living, 4) Life-threatening consequences; urgent intervention indicated, 5) Death related to AE.

ii Relationship

Relatedness refers to the extent to which an adverse event is considered to be related to the intervention or study procedures. An adverse event is considered related if there is a reasonable possibility that the event may have been caused by the procedure. Note that the term "suspected" is also means possibly, probably or definitely related to the intervention or study procedures.

The following definitions apply to relatedness:

1. Unrelated
   - Adverse event is clearly due to extraneous causes (e.g., underlying disease, environment)

2. Unlikely (adverse event must meet 2 of the following):
   - Does not have temporal relationship to intervention
   - Could readily have been produced by the participant's clinical state
   - Could have been due to environmental or other interventions
   - Does not follow known pattern of response to intervention
   - Does not reappear or worsen with reintroduction of intervention

3. Possible (adverse event must meet 2 of the following):
   - Has a reasonable temporal relationship to intervention
   - Could not readily have been produced by the participant's clinical state
   - Could not readily have been due to environmental or other interventions
   - Follows a known pattern of response to intervention
4. **Probable** (adverse event must meet 3 of the following):
   - Has a reasonable temporal relationship to intervention
   - Could not readily have been produced by the participant's clinical state or have been due to environmental or other interventions
   - Follows a known pattern of response to intervention
   - Disappears or decreases with reduction in dose or cessation of intervention

5. **Definite** (adverse event must meet 4 of the following):
   - Has a reasonable temporal relationship to intervention
   - Could not readily have been produced by the participant's clinical state or have been due to environmental or other interventions
   - Follows a known pattern of response to intervention
   - Disappears or decreases with reduction in dose or cessation of intervention and recurs with re-exposure

### iii Expectedness

An **unexpected** event is one that has not been documented previously as an established adverse reaction to the study intervention and that is not recognized as part of the natural progression of the disease. A particular event may also be considered unexpected if it has a higher severity grade than what has been documented or identified previously.

#### 6.e Data Collection Procedures for Adverse Events and Unanticipated Problems

The clinical site staff will report all serious adverse events and unanticipated problems on the trial data collection forms. These events include those related to red blood cell transfusion including those specified in the informed consent form and those that are related to recent myocardial infarction. All of the expected SAEs are recorded on the in-hospital and the 30-day follow-up data collection forms. Site personnel are required to report and document all unexpected SAEs and unanticipated problems to the DCC. The DCC will send all unexpected SAEs (as reported by the site) to the study Medical Monitor for final assessment of severity, relatedness, and expectedness. The Medical Monitor will remain masked to the transfusion strategy while making his/her evaluation of the SAE.
6.1 Reporting Procedures

All reported SAEs and unanticipated problems will be included in systematic reporting to the DSMB on a semi-annual basis. This includes adverse events and problems previously transmitted through expedited reporting.

The following three classes of events need to be reported to the NHLBI, the DSMB and the Local IRB in an expedited manner: 1) Fatal or life threatening unexpected suspected SAE, 2) Non-fatal, non-life threatening unexpected suspected SAE, and 3) Unanticipated problem. Fatalities that are related to blood transfusions must also be reported to the FDA within 7 days according to the guidelines (http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074947.htm).

The site personnel will complete and submit a SAE form to the DCC within 72 hours of learning of the event whenever the event is both serious and unexpected. In cases where the event is not serious but places the patient at greater risk of physical, psychological, economic, or social harm, and is both unexpected and related to the study, the site PI will fill out an Unanticipated Problem form within 14 days of learning about the problem. SAE forms are forwarded along with relevant patient history data to the Medical Monitor for review. The study Medical Monitor will assess the severity, relatedness, and expectedness of the event within 48 hours. Following the Medical Monitor’s feedback on the expectedness and relatedness of the SAE, the DCC will complete an SAE report categorized as serious, unexpected and related. A report will also be sent for unanticipated problems. The DCC will send the reports to the NHLBI DSMB Executive Secretary and the NHLBI Medical Monitor for review. All reporting (from the time that the Site learns about the event until it is reported to the NHLBI, DSMB, FDA and IRBs) will follow the NHLBI DSMB established timelines as specified in (https://www.nhlbi.nih.gov/research/funding/human-subjects/adverse-event) as shown in Appendix 2.

If other SAEs are noted to occur with abnormally high frequency during the trial, these will be reported promptly by the MINT DCC to the DSMB, and the NHLBI DSMB Executive Secretary and the NHLBI Medical Monitor. Upon receipt of an expedited report, the DSMB chair will decide whether the event should be discussed at the next scheduled DSMB meeting or discussed as soon as possible at an ad hoc meeting.

IRB actions regarding the MINT trial will be communicated to the NHLBI Project Officer and NHLBI Executive Secretary in an expedited fashion. If the IRB or ethics board at any MINT site, CCC or...
DCC takes action regarding the MINT trial (e.g., the IRB places a hold on the trial or suspends the trial), the site will report this to the CCC within 24 hours of the action. This will be communicated by telephone and with an urgent help desk ticket through the MINT trial data management system. The Site will submit written documentation from the IRB, an explanation of the circumstances, and a plan of action to the CCC within 72 hours. The CCC will promptly communicate this information to the DCC and the NHLBI project officer. The DCC is responsible for notifying and the NHLBI Executive Secretary. A written report describing the IRB decision, the rationale for the decision and the plan of action based on this decision will be submitted to the NHLBI project officer and the NHLBI Executive Secretary within 7 days of the IRB action.

6.g Adverse Event Reporting Period

All randomized patients will be followed by the trial for 30-days from randomization, and vital status will be ascertained at 6 months from study enrollment. Serious adverse events that occur during the 30-day time period and all deaths up to 6 months will be reported.

6.h Post-study Adverse Event

MINT will not collect or report information about adverse events that occur more than 30-days after randomization with the exception of death which will be reported through 6 months after randomization. Reporting of Adverse events will cease at the conclusion of the MINT trial.

E7 Study Outcome Measurements and Ascertainment

7.a Definitions of Outcomes

i Myocardial Reinfarction

Myocardial reinfarction will be classified by the Clinical Events Committee using The Joint European Society of Cardiology/American College of Cardiology Committee definitions. (47) Patients with reinfarction will need to demonstrate a fall in the troponin value and then a subsequent rise of at least 20% with additional evidence (new ECG changes, imaging evidence, clinical history) as in the MI definition to diagnose a new event. Myocardial reinfarction will be classified as ST-segment elevation or non-ST Segment elevation.
ii  Death and Cause of Death

For each death, the cause will be determined by the site personnel into one of three categories (47): cardiovascular death (e.g., congestive heart failure, dysrhythmia), noncardiovascular death (e.g., infection, cancer), or undetermined cause of death. Information about the specific cause of death will also be collected.

iii  Unscheduled Coronary Revascularization (unstaged)

Ischemia driven, unscheduled coronary revascularization (coronary artery bypass surgery or PCI) within 30 days of randomization will be recorded by the sites. Prior to randomization, the site will record if a coronary revascularization is planned (staged). All coronary revascularization procedures will be recorded, but an elective planned staged procedure will not be included as an outcome. Information about the reason for the procedure will also be collected to ensure that the revascularization was done to treat ischemic heart disease.

iv  Readmission to Hospital, overall and for primary cardiac diagnosis

All re-admissions to the hospital that had not been planned prior to randomization will be captured, and the primary diagnosis for each hospitalization will be classified as: ischemic cardiac diagnosis (e.g., myocardial infarction, unstable angina), non-ischemic cardiac diagnosis (e.g. heart failure) or non-cardiac.

v  Unstable Angina

The MINT trial sites will use 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials to define unstable angina. (47) To diagnose unstable angina requires that four criteria be met: 1) worsening ischemic discomfort, 2) unscheduled hospitalization, 3) negative cardiac biomarker, 4) objective evidence of myocardial ischemia.

vi  Congestive Heart Failure

Sites personnel will use 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials to define congestive heart failure. (47) New or worsening symptoms of congestive heart failure on presentation (increasing dyspnea, paroxysmal nocturnal dyspnea, orthopnea), has objective evidence of new or worsening heart failure, and receives initiation or intensification of treatment specifically for heart failure.
vii TIA or Stroke

The 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials will be used to define stroke. (47) A transient ischemic attack (TIA) is defined as “a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction.” Stroke is defined on the basis of the presence of acute infarction as demonstrated by imaging or based on the persistence of symptoms more than 24 hours.

viii Deep Venous Thrombosis or Pulmonary Embolism

Deep vein thrombosis will be diagnosed if duplex ultrasound, magnetic resonance venogram (MRV), or venogram is definite or probable positive. Site investigators will record if location is proximal or distal. Pulmonary embolism will be diagnosed with a high probability ventilation perfusion lung scan, CT scan, or pulmonary angiogram.

ix Bleeding

Major bleeding will be defined as 1) fatal bleeding, and/or 2) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or 3) bleeding causing a drop in hemoglobin concentration of 2 g/dL or greater (51) from the last hemoglobin concentration prior to randomization to the nadir hemoglobin concentration during hospitalization or up to 30 days post randomization. The drop in hemoglobin concentration will account for each unit of red blood cell transfusion transfused by subtracting 1 g/dL for each unit administered.

x Infections

x.1 Pneumonia

Pneumonia will be diagnosed using CDC criteria (48) which includes radiographic abnormalities and combination of symptoms (i.e., cough), signs (i.e., fever, tachypnea, or laboratory abnormalities (i.e., white blood cell count, hypoxemia).

x.2 Blood Stream Infection

Blood stream infection will be defined using CDC criteria which includes a recognized pathogen cultured from 1 or more blood cultures and organism cultured from blood is not related to an infection at another site, at least 1 of the following signs or symptoms: fever, chills, or hypotension and signs...
and symptoms and positive laboratory results are not related to an infection at another site and common skin contaminant is cultured from 2 or more blood cultures drawn on separate occasions.

x.3 Urinary Tract Infection

Urinary Tract Infection will be defined using CDC criteria (48) which include one of the following signs or symptoms: fever (>38.0°C) or localized pain or tenderness, and laboratory evidence for infection.

xi Length of Stay and Intensive Care Unit Days

The trial will collect the number of days post randomization that patient is in the hospital and in intensive care unit.

xii Quality of Life

The EuroQol questionnaire (EQ-5D), a standardized instrument that measures health related quality of life in 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, will be used as a measure of patient perceived global health status 30 days after randomization.

7.b Ascertainment

Relevant data will be collected from the medical record during the index hospitalization. During the first 3 days following randomization (or hospital discharge if sooner) active surveillance is performed to ensure all occurrences of myocardial reinfarction are detected. It is required that the site obtains troponin levels (every 12 hours for 1 day, and then daily for the next 2 days) and electrocardiograms (daily for the first 3 days). These results, in combination with any additional cardiac biomarkers for necrosis and electrocardiograms and medical findings, will be reviewed by the Clinical Events Committee for each randomized patient, irrespective of a site identified event. We will therefore be able to identify myocardial reinfarction events that were not clinically recognized, in addition to those had been.

Study staff will contact the patient at 30 days to ascertain vital status, administer the quality of life questionnaire, and determine if there has been a subsequent hospital admission. Study staff will obtain and review the medical records for each readmission and record all relevant data and identify the study outcomes. If there is a suspect cardiac event the staff will submit de-identified copies of the documentation (from either the index admission or the readmission) for the Clinical Events Committee.
adjudication. Study staff will perform a final follow-up contact at 6 months following randomization to ascertain the patient's vital status.

**E8 Baseline and Intervention Clinical Characteristics**

Baseline demographic (e.g., age, gender, race), co-morbidity (e.g. cardiovascular risk factors), characteristics of cardiac disease (e.g., left ventricular function, number of coronary vessels obstructed), renal disease, and medications (e.g., aspirin, P2Y12 receptor inhibitor, anticoagulant, beta-blocker statins) will be collected to reflect patient status at the time of randomization. Characteristics describing the study intervention including red blood cell transfusion information (e.g. expiration date, leukoreduction, storage solution, ABO) will be recorded. In hospital, hemoglobin levels and the number and timing of transfusions will be recorded for the two assigned transfusion strategies.

**F Statistical Plan**

**F1 Sample Size Determination and Power**

In the MINT pilot trial, the composite 30-day rate of death and myocardial infarction was 16.4%. Higher rates were observed in the Kaiser System preliminary data. Thirty-day rates of 16.4%, 18%, or 20% are reasonable for this trial since the proposed study population will not exclude the sickest patients as was done in the MINT pilot study. Using a two-sided inequality test and a simple chi-square statistic with alpha=0.05, we determined the samples sizes required to provide 80% and 90% power to detect varying relative reductions in the 30-day event rates for death and myocardial infarction between the two assigned treatment groups. Based on these estimates, we plan to enroll a sample of 3500 patients. If the rate of missing outcome data is no more than 5%, the trial would have 3324 patients with analyzable outcome data at 30-days. Assuming an overall event rate of 16.4%, the trial will have 80% power to detect a 20% relative reduction (i.e. 18.2% vs. 14.6%) and >90% power to detect a 25% relative reduction. If the overall event rate is 18%, then the trial will have >80% power to detect a 20% relative reduction (i.e. 20% vs. 16%), and if the overall event rate is 20%, the trial will have close to 90% power to detect 20% relative reduction (i.e. 22.2% vs. 17.8%). We also performed
a simulation study to compute the power for a log binomial model with a random intercept for site and a final alpha-level=0.045 to account for the interim monitoring. We simulated 1000 trials where each trial had 60 strata representing the sites, 56 participants within each stratum (i.e. N=3360 patients in total), and a mean intra-class correlation (ICC) of 0.05 to 0.08. The simulations indicate that the power is comparable for the proposed log binomial model and the simple chi-square statistic used for the original sample size calculations. Based on the simulations, the trial will have 81% power to detect a 20% relative reduction from 18.2% to 14.6%, and 90% power to detect a 25% relative reduction from 18.2% to 14.0%. In addition, the trial will have 85% power to detect a 20% relative reduction from 20% to 16%, and 89% power to detect a 20% relative reduction from 22.2% to 17.8%.

This pragmatic randomized clinical trial has excellent power to detect clinically meaningful differences between the two transfusion strategies with respect to the critical 30-day composite outcome of death and myocardial infarction on both the absolute and the relative scales. After half of the patients have been enrolled and followed, we will monitor the overall event rate in the trial to ensure that the trial has adequate power to detect clinically relevant treatment effects.

**F2 Interim Monitoring and Early Stopping**

The DSMB will review interim analyses of the outcomes by assigned treatment group annually. The interim monitoring is designed to test for evidence of beneficial effect with either treatment strategy while maintaining the overall type I error at the pre-specified level. Stopping rules are based on the information (i.e. number of primary outcome events) that has accumulated by each inspection time and the shape of the predetermined alpha-spending function. We recommend that the Lan-DeMets approach be used to allocate the type I error (i.e. alpha-level) at each interim time point and use of O'Brien Fleming monitoring boundaries. The DSMB may advise early termination of the trial for safety reasons or make other recommendations regarding modifications to the protocol.

The MINT trial will have 4 years of recruitment with a goal of enrolling N=3500 patients by March 2021. With this timeline, we propose that formal statistical interim monitoring will occur in May or June of 2018, 2019, and 2020 based on N=298 patients enrolled through March 1, 2018, N=872 patients enrolled through March 1, 2019, and N=1905 patients enrolled through March 1, 2020, respectively. All calculations assume an overall trial alpha of 0.05.

With an alpha-spending method, the alpha level to be used at any given look is based upon the amount of information available at the monitoring time. Once alpha is calculated, boundaries for the
standardized Z-test statistic are constructed. A standardized Z-test statistic is calculated based on the estimated relative risk from the log-binomial model which includes assigned transfusion strategy (according to the intention to treat principle) as the independent variable. If the observed Z-test statistic crosses the boundary the difference is considered statistically significant at that monitoring time. The “α spending function approach” allows the number and frequency of monitoring times to be changed at any point during the trial.

Based on the anticipated accrual shown in Appendix 3, below is the table of the expected percent of information, estimated number of participants, the Z-test statistic boundary level and the corresponding alpha spent based on the O’Brien-Fleming boundaries.

**Estimated Boundary Values at Each Interim Monitoring Time Point**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Information Level</th>
<th>O’Brien Fleming Boundary Values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proportion</td>
<td>Number Recruited</td>
</tr>
<tr>
<td>1</td>
<td>0.0900</td>
<td>298</td>
</tr>
<tr>
<td>2</td>
<td>0.2500</td>
<td>872 ±4.33</td>
</tr>
<tr>
<td>3</td>
<td>0.5400</td>
<td>1905 ±2.84</td>
</tr>
<tr>
<td>4</td>
<td>1.0000</td>
<td>3500 ±1.97</td>
</tr>
</tbody>
</table>

The O’Brien and Fleming (1979) repeated significance tests combined with the Lan and DeMets (1983) flexible alpha-spending curves are proposed due to their common usage and their conservative nature when the amount of accumulated data in the trial is small. They are designed to stop earlier in the trial if there is overwhelming evidence that there is a difference between the two treatment groups. The ability to detect a difference between the groups becomes easier as the amount of information in the trial increases.

The form of the O’Brien-Fleming alpha –spending function is:

\[
\alpha(k) = 2 - 2\phi \left( \frac{Z_{\alpha/2}}{\sqrt{i_k}} \right)
\]

where: \( \alpha(k) \) = cumulative alpha at inspection k  
\( k \) = inspection number  
\( \phi(x) \) = the cumulative distribution function of the standard normal curve evaluated at \( x \).
\( Z_\alpha \) = the value of the standard normal curve where \( \alpha \) is the area in the tail

\( i_k \) = the amount of information accumulated in the trial at inspection \( k \)

We assume a symmetric 2-sided boundary, with each side spending \( \alpha = 0.025 \). Below are plots of the cumulative O’Brien-Fleming alpha-spending curve and the corresponding boundary plot. We assume a symmetric 2-sided boundary, with each side spending \( \alpha = 0.025 \).
It is possible that the test statistic will cross the monitoring boundary. Statistical interim monitoring results should be taken as one component to the decision as to whether or not to stop a trial. To stop the trial for efficacy, results should be definitive enough to be able to change clinical practice. The DSMB will use the monitoring information to determine its recommendation to NHLBI. The DSMB can recommend that the MINT trial should continue as proposed, that the MINT protocol should be modified based on the results seen in one treatment comparison or in some well-defined subgroup of patients, or that the MINT trial should be terminated early. The final decision to stop trial rests with the NHLBI. If recommendation is to stop the trial, the MINT trial principal investigators shall be consulted before a final decision is made.

In order to ensure that the MINT trial has adequate power, an interim analysis to assess sample size will be conducted after when half of the participants are projected to have completed the 30-day follow-up. Revised sample size estimates will be calculated based on the original power and effect size estimates from the trial hypothesis (80% power to detect a RR=0.80) and on the observed overall event rate (i.e. the two transfusion groups combined). The DSMB will evaluate whether the trial sample size needs to be increased in order to restore power to maintain the ability to detect a clinically meaningful effect size.
Since the MINT trial compares two established transfusion strategies with different resource and cost implications, a null result from a well-powered trial would be important for establishing treatment guidelines and policy. Thus, no interim futility analyses will be conducted in the MINT trial.

F3 Analysis Plan

A Screening Log will be developed to include the number of patients with acute myocardial infarction and hemoglobin level < 10 g/dL, eligibility and enrollment status. Proportions of eligible and enrolled patients will be presented, and reasons why patients are not eligible or enrolled in the trial will be tabulated. Enrollment patterns will be compared across clinical sites and patient groups defined by sex and race/ethnicity. The baseline characteristics and co-interventions of the patients who are randomized in the MINT trial will be described, and characteristics of patients in the two assigned treatment groups will be compared. The proportion of enrolled patients who adhere to the assigned intervention will be ascertained by evaluating the hemoglobin levels and the number of units of blood transfused during the index hospitalization. The intention-to-treat principle will be used to compare the primary outcome (the composite of all-cause mortality and myocardial infarction by 30 days from randomization) and each pre-specified secondary outcome by the randomized transfusion strategy groups. A select number of subgroup analyses will be performed based on baseline factors identified prior to the initiation of the trial.

F4 Statistical Methods

4.a Baseline Characteristics of the Enrolled Patient Sample

Descriptive statistics will be examined for all relevant baseline measures collected on the MINT randomized patients. Transformations of measures will be considered on the basis of distribution diagnostics and outlier analysis. The baseline characteristics and co-interventions of the patients in the overall study will be described using frequencies, proportions, means and standard deviations, or medians and first and third quartiles. Characteristics of patients in the two arms of the trial will be compared using chi-square statistics for categorical variables and t-tests or Wilcoxon rank-sum statistics for continuous variables.
4.b Adherence to Assigned Intervention

The mean hemoglobin concentration at 1, 2, and 3 days post-randomization will be compared between the assigned treatment groups with a Student's t-test. Mixed random effect models will be used to describe the daily mean hemoglobin concentrations during the initial hospitalization following randomization and to compare these repeated measures by assigned treatment group. The mean number of red blood cell transfusions in each randomized treatment group will be described, and a simple Poisson test will be used to test whether the number of units of blood differs significantly by assigned transfusion strategy.

4.c Primary Outcome Analysis

The intention-to-treat principle will be used for all randomized transfusion strategy comparisons of study outcomes. A two-sided test will be used with an alpha-level=0.05 for the primary outcome, the composite of all-cause mortality and myocardial infarction (death/MI) by 30 days from randomization. The 30-day event rate for the primary outcome will be compared by assigned transfusion strategy using an unadjusted log-binomial regression model with a fixed effect variable for assigned treatment strategy and a random effect for clinical site. The primary analysis will involve the estimated relative risk and significance level obtained from the model accounting for interim monitoring and missing data. Event rates, the relative risk and the absolute difference will be from the observed data will also be presented, and 95% confidence intervals will be calculated.

If significant imbalances in baseline risk factors are detected between the two randomized treatment groups (p<0.05), multivariable log-binomial regression will be used to adjust for potential confounding factors as a sensitivity analysis. If adherence to the protocol is lower than expected, a per protocol analysis, including only patients who undergo transfusion according to their assignment and adjusting for baseline factors that are associated with adherence to the treatment protocol, will be conducted as a sensitivity analysis.

4.d Analysis of Secondary and Tertiary Outcomes

Event rates, the relative risk and the absolute difference between transfusions strategy groups for the dichotomous secondary and tertiary outcomes will be calculated with their 95% confidence intervals using log-binomial regression methods accounting for clinical site with random effects. The length of hospital stay from randomization and from admission will be analyzed using non-parametric Wilcoxon
rank sum tests, and long-term mortality will be analyzed with Kaplan-Meier methods and the log rank statistic. The Kaplan-Meier estimated mortality rate in each treatment group at 180 days, the absolute difference between the assigned treatment groups at 180 days, and the 95% confidence interval for the difference will be presented. Transfusion strategy comparisons of the EQ-5D quality life measures at 30 days will be based on t-tests or the Wilcoxon rank sum test. No adjustment of the alpha level will be made for the secondary and tertiary analyses. Rather the results will be interpreted based upon the observed findings, their designation as secondary or tertiary outcomes, and in comparison to the primary outcome result.

The secondary outcomes include: 1) all-cause mortality within 30 days; 2) myocardial reinfarction within 30 days; and 3) the composite outcome of all-cause mortality, nonfatal myocardial reinfarction, ischemia driven unscheduled coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), or readmission to the hospital for ischemic cardiac diagnosis within 30 days.

The tertiary outcomes include: 1) all-cause mortality, nonfatal myocardial reinfarction, and unstable angina (i.e. acute coronary syndrome) 2) ischemia driven unscheduled coronary revascularization within 30-days; 3) readmission to the hospital for ischemic cardiac diagnosis, 4) congestive heart failure within 30 days; 5) unscheduled readmission to hospital for any reason within 30 days; 6) each of the individual cardiovascular outcomes of stroke, pulmonary embolism or deep venous thrombosis, and bleeding within 30 days; 7) each of the individual infectious outcomes of pneumonia, bloodstream, and urinary tract within 30 days; 8) each of the individual in-hospital outcomes of length of hospital stay post randomization and number of days in intensive care unit; 9) patient reported quality of life measures based on the EuroQol questionnaire (EQ-5D) at 30 days; and 10) all-cause mortality at 6-months.

4.e Missing Outcome Data

For the analysis of the primary outcome, standard multiple imputation methods will be used to impute missing 30-day data. We expect that missing 30-day outcome data will be very low in this trial. All patients should have non-missing death and MI data from randomization to hospital discharge. Markov Chain Monte Carlo (MCMC) multiple imputation methods will be used to impute the missing 30-day outcome values (yes/no) for death and MI. Specifically, a log-binomial regression model to estimate the relationship between the outcome and key covariates (observed baseline and
in-hospital variables that are clinically relevant and related to the “missingness” of the 30-day outcomes) in the participants with full data. This model will be used to predict the probability of the outcome for participants who are missing the 30 day outcomes. Based on these probabilities, ten imputed data sets will be created. A log-binomial model with random effects for site will be estimated for each imputed data set, and the results will be pooled to obtain a single estimate of treatment effect with an appropriately adjusted standard error. As a sensitivity analysis, a log-binomial model with random effects for site will be created based on the non-missing 30-day death/MI data. Missing data will not be imputed for the analyses of the secondary and tertiary hypotheses unless critical issues are noted while investigating the missing 30-day data.

4.f Subgroup Analyses

Subgroup analyses will be performed based on baseline factors identified prior to the initiation of the trial. Clinically relevant subgroup variables include: ST segment elevation MI / non ST segment elevation MI, Universal Definition type 1 MI / type 2 MI, type 4b and 4c, baseline hemoglobin level (<8, 8-9, 9-10 g/dL), revascularization for treatment of index MI, bleeding, sex, race/ethnicity (White, Black, Other Race and Hispanic, non-Hispanic), age (<70, ≥70 years old), left ventricular dysfunction, diabetes status, and creatinine clearance (eGFR <30, 30-59, ≥60). The 30-day event rates by assigned transfusion strategy will be compared within each pre-defined subgroup. The reported significance-level will account for the number of treatment comparisons conducted in the study using the false discovery rate (FDR) algorithm developed by Benjamini and Hochberg. In addition, for each subgroup variable, a log-binomial regression model including treatment assignment, subgroup variable and the interaction between the subgroup variable and treatment assignment will be created, and the significance of the interaction term will be used to test whether the randomized treatment effect is significantly modified by the designated subgroup variable. Cox proportional hazards regression models will be created with similar covariates in order to test whether the effect of the randomized transfusion strategy for 6-month mortality varies significantly according to the pre-specified subgroup variables.

4.g Combining Vanguard and Main Trial Data

In 2016, the Canadian Institutes of Health Research (CIHR) funded a MINT Pilot trial. This pilot is coordinated by the University of Montreal, and the clinical sites are in Canada. The DCC and CCC have collaborated with the University of Montreal to ensure that the protocol (eligibility criteria,
interventions, and outcomes) as well as the randomization scheme and the data to be collected are nearly identical to those for the main MINT trial. The CIHR MINT pilot trial was funded to enroll 60 patients. This pilot trial will serve as a “Vanguard phase” for the MINT trial and will allow us to evaluate the feasibility of the MINT protocol. After the MINT protocol is approved by the DSMB/NHLBI and the appropriate ethics committees in Canada, patients randomized at the Canadian Sites will be enrolled as MINT participants. All data collection and data coordination for the MINT participants will occur through the University of Pittsburgh DCC. Patients who are randomized prior to the transition date will remain CIHR pilot trial participants throughout their follow-up. The complete Vanguard datasets housed at the University of Montreal will be transferred to the University of Pittsburgh DCC. The Vanguard patient data will be merged with the MINT trial data based on rigorous comparisons of variable definitions and variable coding. All Vanguard patients will be included in the target sample size and presented in DSMB and published data reports for the MINT trial.

F5 Unblinding Procedures

Patients and providers are not blinded in the MINT trial, and thus unblinding procedures are not required for patient safety. Trial monitors and adjudicators are blinded to transfusion strategy, and the DSMB may choose to be blinded to transfusion strategy as they monitor the outcome data. The Medical Monitor and DSMB can request to be unblinded if they deem this necessary.

G Data Handling and Record Keeping

G1 Confidentiality and Security

Patient identifiers (e.g. name and social security number) will not be sent to the trial DCC, however, some personal health information (e.g. birth date and hospitalization admission date) will be collected centrally. The University of Pittsburgh DCC has a strictly enforced security policy with standard operating procedures addressing key security risk areas. Procedures include password protection, limited access to study computers, encryption, IP restriction, basic or digest authentication, and firewalls between the Internet and the DCC network and servers. Regularly scheduled backups and
archives are performed at least once daily with backup media copies of project files stored off-site in a secure location. Virus detection will be enforced at the DCC. All servers will be connected to uninterruptible power supplies and housed in a computer room with an alarm.

Patient contact information will be maintained exclusively by the local site and stored in a secure location. Only local study staff responsible for the 30 day and 6 month telephone calls will have access to this contact information.

**G2 Training**

DCC personnel at the University of Pittsburgh will work with CCC personnel at Rutgers / Robert Wood Johnson to provide the training necessary for uniform data collection, protocol compliance, and data processing. Major elements to be covered are inclusion and exclusion criteria, procedures and tools to monitor adherence to protocol, randomization procedures, event adjudication procedures, adverse event reporting, methods for extracting data from different sources, follow-up schedules, what to do about missing information, reporting requirements, and use of the Manual of Operations and study website. Instruction will be provided for entering the data, transmitting them to the DCC, interpreting edit reports and correcting data.

On-going training will be required due to the addition of new clinical sites as well as turnover of staff at the existing clinical sites. The CCC and DCC will utilize webinars and conference calls to conduct detailed distance training sessions. On-line protocol and data collection training modules will be available on the trial website, and focused training sessions will be conducted in conjunction with Steering Committee meetings as required. Throughout the trial, there will be regularly scheduled conference calls with the coordinators and data collectors at all sites to discuss issues that arise with protocol and data collection.

**G3 Case Report Forms and Source Documents**

The data collection forms for this trial have been developed to facilitate enrollment and follow-up while still collecting the essential information needed to answer the trial hypotheses. A web-based distributed data management system will be used for data entry. Source documents will be maintained at the clinical site.
**G4 Records Retention**

Trial patient records will be retained at the clinical sites and at the Coordinating Centers for 6 years after MINT data collection is completed.

**G5 Performance Monitoring**

The DCC will monitor study performance. Routine reports will be developed to monitor the ongoing progress of the study including enrollment and retention. Protocol adherence reports include enrollment of ineligible patients, follow-up data collection outside of protocol-defined windows, and deviations from protocol. The timeliness of data collection and data entry is routinely monitored at the DCC using information entered into the data system (evaluation date and data collection date), and information stored in the systems inventory files (dates of entry, verification, and submission). The DCC will provide reports to the MINT CCC and clinical site coordinators including scheduling and delinquency. Inadequate performance of a site will be reported to the CCC and the site. The DCC and CCC will work with the site to find solutions to challenges. The DCC and CCC will evaluate the performance at that site to determine whether corrections have been made. Should problems persist, the Operations Committee will be notified along with recommendations for resolving persisting inadequacies. Trial and site performance reports will be provided to the sites, the CCC, the Steering Committee, and the DSMB.

**H Study Monitoring, Auditing, and Inspecting**

**H1 Study Monitoring Plan**

The CCC will coordinate the study monitoring site visits to each clinical site. In addition, the DCC will conduct data monitoring site visits to clinical sites where specific data issues are identified or data concerns arise based on a risk-based monitoring plan. The risk-based monitoring plan will be based on site performance metrics as well as the results of CCC safety and compliance monitoring visit.

**H2 Auditing and Inspecting**

During monitoring site visits, CCC personnel will review source documents, including informed consent documents, for a random sample of patients and for a defined subset with an exceptional number of inconsistencies identified through the data monitoring processes to confirm that data are
collected and entered accurately. Problems adhering to study protocols, data collection, entry, and management will be identified and corrective procedures will be addressed.

I Study Administration

11 Organization and Participating Centers

1.a Clinical Coordinating Center

The Rutgers Robert Wood Johnson School of Medicine, Division of General Internal Medicine is responsible for clinical coordination of the trial. The responsibilities of the Clinical Coordinating Center are to: 1) Provide administrative and fiscal support for the Clinical Sites; 2) Provide technical, patient assessment and Protocol adherence advice to Clinical Site staff; 3) Assist Clinical Sites to correct problems with recruitment, Protocol adherence and data collection; 4) Participate in site visits; 5) Provide advice about any aspect of the trial; and 6) Lead presentation and publication of study results for the scientific and lay press.

A Canadian subsidiary clinical coordinating center to Rutgers Robert Wood Johnson Medical School will be housed at the University of Montreal. The Canadian Coordinating Center will carry out the clinical coordinating center responsibilities listed above for the Canadian sites and will be supervised by Dr. Paul Hebert and Dr. Jeffrey Carson. The Canadian Coordinating Center will have no data coordinating function.

1.b Data Coordinating Center

The Epidemiology Data Center at the University of Pittsburgh is responsible for the data coordination of the trial. The DCC will provide statistical leadership and resources for data management, quality control, and analysis. The responsibilities of the DCC include: 1) Maintain study website and provide all study materials, including the Manual of Procedures (MOP) and Data Collection Forms; 2) Provide a 24 hour randomization service; 3) Establish and maintain an electronic database to receive study data and to verify for completeness, retrieving any missing data from the centers; 4) Conduct routine data edits; 5) Monitor performance to detect problems with recruitment, protocol adherence and data collection; 6) Participate in site visits; 7) Provide advice about any aspect of the trial; 8) Perform interim and final analyses.
1.c Clinical Consortium

The clinical sites recruiting patients into MINT comprise the Clinical Consortium of participating hospitals. Each site will be led by the Clinical Site Director and Clinical Site Coordinator. The Clinical Site Director and Coordinator will work closely together to assure successful performance of the trial.

The responsibilities of the Clinical Site Director include: 1) To insure that all medical staff involved with the care of myocardial infarction patients are well informed about the trial; 2) To insure that all patients with myocardial infarction are routinely considered for the trial; 3) To insure that the transfusion strategy is followed, i.e., blood is given in the Restrictive Transfusion Strategy only for symptoms from anemia or when the lower threshold is reached and blood is given in the Liberal Transfusion Strategy when Hgb < 10 g/dL; 4) To communicate with Clinical Coordinating Center staff and Data Coordinating Center staff any problems or concerns related to the study; and 5) To assist the Clinical Site Coordinator as necessary.

The responsibilities of the Clinical Site Coordinator include: 1) To identify myocardial infarction patients for the trial; 2) To obtain informed consent from the patient or surrogate; 3) To inform treating staff of the patient’s treatment assignment assigned transfusion strategy; 4) To complete data collection forms and process data edit queries; 5) To perform 30 and 180 day telephone follow-up; 6) To obtain and submit all relevant source documents for the Clinical Event Committee adjudication; 7) To participate in telephone calls with the Clinical Coordinating Center; 8) To train assistant site coordination and other staff at the Clinical Site.

12 Funding Source and Conflicts of Interest

This trial is supported by the National Heart Lung and Blood Institute. All investigators will be required to declare any potential conflicts of interest.

13 Committees

3.a Steering Committee

The primary decision making body of the MINT trial will be the Steering Committee and will include the Principal Investigators of the CCC and DCC, experts in cardiology, transfusion medicine, biostatistics, and the NHLBI project officers. The Steering Committee will have quarterly conference
calls and annual in-person meetings. The group will focus on the science of the study and to review priorities on a regular basis.

3.b Operations Committee

A smaller committee, the Operations Committee, will be a subset of the Steering Committee that will meet approximately twice per month via conference call and will be charged with reviewing operational and scientific issues for the trial and formulating recommendations for consideration by the full Steering Committee. The Operations Committee will be chaired by Dr. Carson and will include DCC PI, selected Steering Committee members, and the CCC and DCC project directors.

The Operations Committee will be empowered to execute operational decisions, and the Operations Committee Chair will have the authority to set meeting agendas and appoint committee chairs as needed. The committee will ensure that recruitment for the network is progressing as planned for the clinical trial. In addition to reviewing monthly recruitment reports and quarterly follow-up data collection reports, the group will make specific recommendations for strategies to improve recruitment and protocol implementation.

3.c Executive Committee

A small Executive Committee will identify high level study design and implementation issues that are to be discussed by the Steering Committee and to resolve issues that require immediate action. The committee will include the PIs of the CCC and the DCC and the lead clinical investigator from the United States and from Canada.

3.d Clinical Events Committee

A Clinical Events Committee will be responsible for adjudication of myocardial infarctions, unstable angina, ischemia driven unscheduled coronary revascularization, and the classification of cause of death in the trial. Committee members will be masked to transfusion strategy assignment when they review and adjudicate patient event packets.

14 Subject Stipends or Payments

Study patients will not receive any stipends or payments
# Study Timetable

This study will require 5 years for completion. The timeline and benchmarks are as follows:

<table>
<thead>
<tr>
<th>Benchmarks</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Planning and Organization Phase 1:</strong> Finalize the Manual of Operations and data collection instruments. Communicate with the Clinical Site Directors at each study site. Obtain IRB approval at clinical sites with assistance from CCC staff. Develop computer software for randomization and data entry.</td>
<td>Months 1-4 (9/1/16 – 12/31/16)</td>
</tr>
<tr>
<td><strong>Planning and Organization Phase 2:</strong> Communicate final study protocol and procedures. Plan and schedule training. Hold annual Collaborators’ Meeting for Clinical Site Directors and Coordinators. Distribute final forms.</td>
<td>Months 5-6 (1/1/17 – 2/28/17)</td>
</tr>
<tr>
<td><strong>Recruitment and Follow-up Phase:</strong> Initiate patient enrollment at the clinical sites. Recruitment will start once a site has IRB approval, an executed contract, and staff have been trained. Continue for 4.0 years, until patient recruitment is completed, or the study is stopped early. Hold annual Collaborators’ Meetings.</td>
<td>Month 7 - Year 4.5 (3/1/17 – 2/28/21)</td>
</tr>
<tr>
<td><strong>Close-out and Analysis Phase:</strong> Complete follow-up and data cleaning. Perform data analysis. Discuss results at Collaborators’ Meeting. Present trial results.</td>
<td>Year 4.5 (3/1/21 – 8/31/21)</td>
</tr>
</tbody>
</table>

The planned accrual timeline, including the target and the cumulative target enrollment for each quarter, is provided in Appendix 3.
J Publication Plan

The Publications Committee will include physicians, scientists, and statisticians involved with the MINT trial. The chair of the committee will rotate bi-annually. This committee will be charged with coordinating the publication of study results and ensuring that these publications move forward according to schedule. Our plan is that the primary results of the trial will be submitted for publication within 9 months of the completion of the trial. This will allow three months for data management and cleaning, three months for analysis and three months for manuscript preparation.

Dr. Carson will coordinate the effort for the primary results paper and the author byline will include the writing team “and the MINT Trial Investigators”. The primary results writing team will be comprised of the members of the Steering Committee. An appendix listing all of the MINT investigators including the Steering Committee members, the Site Investigators, the NIH program officers, the DSMB and other relevant contributors to the trial will appear at the end of the paper.

There will be additional papers that evaluate secondary hypotheses. The Publications Committee will review proposals for all non-primary papers. Approval of a paper proposal will require that the topic is clinically relevant, the paper does not overlap with an existing topic, and the general methodology is sound. Secondary papers will have individually named authors and will include “for the MINT Trial Investigators” in the author byline. The investigators who propose the concept will automatically be part of the writing team. Investigators from the Steering Committee and the Sites will have the opportunity to sign up for proposed writing teams. If more than 12 investigators sign up for an individual writing group, the Publications Committee will allocate investigators to writing teams based on contributions to the trial and expertise on the specific topic.

In order to ensure that the trial is using its resources to report the topics of greatest clinical relevance, the trial Investigators will be asked for ideas for papers and the Steering Committee will be asked to identify the ten most important papers. If a paper on this list is not moving forward according to schedule, the Publication Committee will notify the Steering Committee and may recommend a change in leadership for the paper. The Steering Committee will make final decisions about the leadership for papers.
K References


Appendices
# Appendix 1: MINT Data Elements by Study Time Point

<table>
<thead>
<tr>
<th>Study Outcomes</th>
<th>Screening</th>
<th>Baseline</th>
<th>Randomization</th>
<th>12 hours Post Randomization</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Daily Up to 30 Days</th>
<th>Hospital Discharge/30 Days</th>
<th>30 Day Follow-up</th>
<th>6 Month Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirm Eligibility</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin Level(^a)</td>
<td></td>
<td>X(^b,c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin Level(^p)</td>
<td></td>
<td>X(^b,c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG(^a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implement Transfusion Strategy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Outcomes</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of Life (EQ-5D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital Status</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment of AEs and UPs</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety Monitoring</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) in addition to required time points, all performed for clinical reasons are collected

\(^b\) required, if still in hospital

\(^c\) within the 24 hours prior to randomization

\(^d\) including unit information (e.g., leukoreduction)

\(^e\) mortality outcome only
## Appendix 2: SAE and UP Event Reporting Timelines

<table>
<thead>
<tr>
<th>What Event is Reported</th>
<th>When is Event Reported</th>
<th>By Whom is Event Reported</th>
<th>To Whom is Event Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatal or life-threatening unexpected, suspected serious adverse reactions</td>
<td>Within 7 calendar days of initial receipt of information</td>
<td>Investigator</td>
<td>Local/internal IRBs, NHLBI and/or Data Coordinating Center (DCC)</td>
</tr>
<tr>
<td>Non-fatal, non-life-threatening unexpected, suspected serious adverse reactions</td>
<td>Within 15 calendar days of initial receipt of information</td>
<td>Investigator</td>
<td>Local/internal IRBs, NHLBI and/or DCC</td>
</tr>
<tr>
<td>Unanticipated adverse device effects</td>
<td>Within 10 working days of investigator first learning of effect</td>
<td>Investigator</td>
<td>Local/internal IRBs, NHLBI and/or DCC</td>
</tr>
<tr>
<td>Unanticipated Problem that is not an SAE</td>
<td>Within 14 days of the investigator becoming aware of the problem</td>
<td>Investigator</td>
<td>Local/internal IRBs, NHLBI and/or DCC</td>
</tr>
<tr>
<td>All Unanticipated Problems*</td>
<td>Within 30 days of the IRB's receipt of the report of the UP from the investigator</td>
<td>IRB</td>
<td>OHRP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Investigator</td>
<td>External IRBs</td>
</tr>
</tbody>
</table>

1. Designee is appointed by the sponsor; for example, DCC, CRO.
2. Per OHRP guidance: only when a particular AE or series of AEs is determined to meet the criteria for an UP should a report of the AE(s) be submitted to the IRB at each institution under the HHS regulations at 45 CFR part 46. Typically, such reports to the IRBs are submitted by investigators.
3. Investigators should also take into account local IRB guidance if reporting timelines for UPs are shorter than OHRP guidance.
L3 Appendix 3: Accrual Timeline Milestones

The principles guiding the accrual timeline are as follows. The specific target numbers are provided in the table.

- Recruitment will start 6 months after funding of the trial
- 50% of the projected sites will initiate recruitment between month 6 and 12
- All sites will be recruiting by month 18
- Recruitment will extend for 4 years
- The recruitment rate will get faster over time.
- Total sample size is 3500 patients.

<table>
<thead>
<tr>
<th>Date</th>
<th>Proposed Target Accrual</th>
<th>Proposed Cumulative Accrual</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/1/17</td>
<td>Start</td>
<td>Start</td>
</tr>
<tr>
<td>6/1/17</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>9/1/17</td>
<td>63</td>
<td>106</td>
</tr>
<tr>
<td>12/1/17</td>
<td>86</td>
<td>192</td>
</tr>
<tr>
<td>3/1/18</td>
<td>106</td>
<td>298</td>
</tr>
<tr>
<td>6/1/18</td>
<td>121</td>
<td>419</td>
</tr>
<tr>
<td>9/1/18</td>
<td>136</td>
<td>555</td>
</tr>
<tr>
<td>12/1/18</td>
<td>151</td>
<td>706</td>
</tr>
<tr>
<td>3/1/19</td>
<td>166</td>
<td>872</td>
</tr>
<tr>
<td>6/1/19</td>
<td>191</td>
<td>1063</td>
</tr>
<tr>
<td>9/1/19</td>
<td>227</td>
<td>1290</td>
</tr>
<tr>
<td>12/1/19</td>
<td>275</td>
<td>1565</td>
</tr>
<tr>
<td>3/1/20</td>
<td>340</td>
<td>1905</td>
</tr>
<tr>
<td>6/1/20</td>
<td>380</td>
<td>2285</td>
</tr>
<tr>
<td>9/1/20</td>
<td>400</td>
<td>2685</td>
</tr>
<tr>
<td>12/1/20</td>
<td>405</td>
<td>3090</td>
</tr>
<tr>
<td>3/1/21</td>
<td>410</td>
<td>3500</td>
</tr>
</tbody>
</table>